Explanipedia

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial Open

Rebecca A. Clark, S. T. Davies, Jorge Labrador, Paul Loubet, S. Martinez , et al. · 2024

Background We evaluated co-administration of adjuvanted seasonal quadrivalent influenza vaccine (FLU-aQIV) and respiratory syncytial virus (RSV) prefusion F protein-based vaccine (RSVPreF3 OA) in ≥65-year-olds. Methods This phase 3, open-l…

Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults Open

Murdo Ferguson, Alexander G. Murray, Lew Pliamm, Lars Rombo, Johan Berglund , et al. · 2024

This study demonstrated lot-to-lot immunogenicity consistency of three RSVPreF3 OA vaccine lots and indicated that the vaccine had an acceptable safety profile.ClinicalTrials.gov: NCT05059301.

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons Open

Michael G. Ison, Alberto Papi, Eugene Athan, Robert G. Feldman, Joanne M. Langley , et al. · 2024

Background The adjuvanted RSV prefusion F protein–based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) in ≥60-years-olds over 1 RSV season. We evaluated efficacy and safety of 1 RSVPreF…

Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions Open

Robert G. Feldman, Raffaele Antonelli Incalzi, Katie Steenackers, Dong‐Gun Lee, Alberto Papi , et al. · 2023

Background Older adults with chronic cardiorespiratory or endocrine/metabolic conditions are at increased risk of respiratory syncytial virus (RSV)-related acute respiratory illness (RSV-ARI) and severe respiratory disease. In an ongoing, …

Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study Open

Isabel Leroux‐Roels, Marc Van Ranst, Corinne Vandermeulen, Carline Vanden Abeele, Nathalie De Schrevel , et al. · 2023

Background In the previous (parent) study, 2 doses of different formulations of an investigational vaccine against respiratory syncytial virus (RSVPreF3 OA) were well tolerated and immunogenic in older adults. This multicenter phase 2b ext…

Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial Open

Shady Kotb, Miwa Haranaka, Nicolas Folschweiller, Phoebe Nakanwagi, Céline Verheust , et al. · 2023

NCT04090658.

Retraction Note: Selective Priming of Tumor Blood Vessels by Radiation Therapy Enhances Nanodrug Delivery Open

Sijumon Kunjachan, Shady Kotb, Robert Pola, Michal Pechar, Rajiv Kumar , et al. · 2022

Author Correction: Selective Priming of Tumor Blood Vessels by Radiation Therapy Enhances Nanodrug Delivery Open

Sijumon Kunjachan, Shady Kotb, Robert Pola, Michal Pechar, Rajiv Kumar , et al. · 2020

RETRACTED ARTICLE: Selective Priming of Tumor Blood Vessels by Radiation Therapy Enhances Nanodrug Delivery Open

Sijumon Kunjachan, Shady Kotb, Robert Pola, Michal Pechar, Rajiv Kumar , et al. · 2019

La médecine de précision en oncologie : challenges, enjeux et nouveaux paradigmes Open

Stéphanie Cox, Marina Rousseau-Tsangaris, Nancy Abou-Zeid, Stéphane Dalle, Pierre Leurent , et al. · 2019

Targeted Drug Delivery by Radiation-Induced Tumor Vascular Modulation Open

Sijumon Kunjachan, Shady Kotb, Rajiv Kumar, Robert Pola, Michal Pechar , et al. · 2018

Effective drug delivery is severely restricted by the presence of complex pathophysiological barriers in solid tumors. In human pancreatic adenocarcinoma, mature and hypopermeable tumor blood vessels limit the permeation and penetration of…

Safety Evaluation and Imaging Properties of Gadolinium-Based Nanoparticles in nonhuman primates Open

Shady Kotb, Joao Piraquive, Franck Lamberton, François Lux, Michaël Verset , et al. · 2016

In this article, we report the safety evaluation of gadolinium-based nanoparticles in nonhuman primates (NHP) in the context of magnetic resonance imaging (MRI) studies in atherosclerosis bearing animals and healthy controls. In healthy NH…

Key clinical beam parameters for nanoparticle-mediated radiation dose amplification Open

Alexandre Detappe, Sijumon Kunjachan, Pascal Drané, Shady Kotb, Marios Myronakis , et al. · 2016

Correction: Corrigendum: Laser spectrometry for multi-elemental imaging of biological tissues Open

Lucie Sancey, Vincent Motto‐Ros, Benoît Busser, Shady Kotb, Jean‐Michel Benoit , et al. · 2016

Scientific Reports 4: Article number: 6065; published online: 14 August 2014; updated: 22 April 2016 In this Article, B. Busser is incorrectly affiliated with 'Institut Lumière Matière, UMR5306 Université Lyon 1-CNRS, Université de Lyon 69…

Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial Open

Shady Kotb, Alexandre Detappe, François Lux, Florence Appaix, Emmanuel Barbier , et al. · 2016

Nanoparticles containing high-Z elements are known to boost the efficacy of radiation therapy. Gadolinium (Gd) is particularly attractive because this element is also a positive contrast agent for MRI, which allows for the simultaneous use…

Long-Term<i>in Vivo</i>Clearance of Gadolinium-Based AGuIX Nanoparticles and Their Biocompatibility after Systemic Injection Open

Lucie Sancey, Shady Kotb, Charles Truillet, Florence Appaix, M.F. Arthur , et al. · 2015

We previously reported the synthesis of gadolinium-based nanoparticles (NPs) denoted AGuIX (activation and guiding of irradiation by X-ray) NPs and demonstrated their potential as an MRI contrast agent and their efficacy as radiosensitizin…

Shady Kotb YOU? Author Swipe